Why is E. coli the preferred production organism for pharmaceutical-grade pDNA?

E. coli naturally maintains high-copy ColE1-origin plasmids at 500 to 700 copies per cell without requiring the expression system engineering needed for protein production. Its fermentation at GMP scale is well-established, its genetics are fully characterized, and its growth on defined carbon sources supports the transition to animal-origin-free media. No alternative host organism provides comparable plasmid copy number, fermentation scalability, and regulatory precedent for pharmaceutical pDNA manufacturing.

What causes acetate accumulation in E. coli pDNA fermentation and why is it a problem?

Acetate accumulates when glucose uptake exceeds the capacity of the TCA cycle to process the resulting pyruvate oxidatively, diverting carbon through overflow fermentation to acetate and other organic acids. Acetate inhibits E. coli growth at concentrations above 3 to 5 grams per liter, reducing cell density and plasmid yield. Fed-batch operation with controlled glucose feeding prevents the glucose excess that drives overflow metabolism, keeping acetate below inhibitory concentrations throughout the fermentation.

What is animal-origin-free media and why does it matter for GMP pDNA production?

AOF media replaces animal-derived ingredients such as beef peptone and casein hydrolysates with plant-derived or synthetic components, eliminating the BSE and TSE risk that requires extensive supplier qualification under regulatory guidelines. For GMP drug master file submissions to FDA and EMA, AOF media simplifies the raw material risk assessment and reduces the documentation burden for each production lot. Programs should establish AOF media from the start of GMP development rather than planning a later switch, which requires comparability studies.

Why does supercoiled content matter so much for pDNA quality?

The supercoiled isoform is the biologically active form of plasmid DNA: it is more resistant to nuclease degradation, more efficiently taken up by cells in non-viral delivery, and more productive as an in vitro transcription template for mRNA manufacturing. The FDA recommends greater than 80% supercoiled content for gene therapy applications. Downstream processing can selectively remove open circular and linear contaminants, but cannot increase the total pool of supercoiled pDNA beyond what the upstream process produces.

How are endotoxins removed from E. coli-derived pDNA?

Endotoxins, the lipopolysaccharides released from E. coli's outer membrane during cell lysis, are negatively charged amphiphilic molecules that bind anion exchange resins alongside pDNA. Selective elution under conditions that favor pDNA desorption before endotoxin, or anion exchange chromatography operated in a mode where endotoxin is retained while pDNA passes through, are the primary removal strategies. Hydrophobic charge induction chromatography can also separate endotoxin from pDNA based on the hydrophobic character of the lipid A component. Multi-step purification trains typically achieve endotoxin removal to below 1 EU per microgram for injectable applications.

Articles

Optimizing plasmid DNA yields in microbial systems

If mRNA is the software, plasmid DNA is the code. The industry needs a lot more of it at GMP grade. Here is how the fermentation science gets there.

Written byTrevor J Henderson

| 9 min read

A GMP E. coli fermentation suite with stainless steel bioreactors, automated controls, and process monitoring equipment for pharmaceutical plasmid DNA production.

GMP-grade plasmid DNA production in E. coli requires not just high volumetric yield from the fermentation but control of the supercoiled isoform fraction throughout the process. Both objectives must be designed into the fermentation strategy from the outset, because downstream processing can maintain but not substantially recover supercoiled content lost during upstream production.

Flow (2026)

Listen with Speechify

0:00

9:00

Highlights in this article

Key takeaways
How E. coli becomes a plasmid factory: the production biology
What fermentation parameters most affect pDNA yield and supercoiled content?
Animal-origin-free media: eliminating the compliance risk in GMP fermentation
Why does the plasmid isoform ratio matter and how is supercoiled content controlled?
Downstream processing: from alkaline lysis to pharmaceutical-grade pDNA
What quality attributes define a GMP-grade pDNA specification?

Plasmid DNA is the upstream raw material that every mRNA therapeutic and gene therapy program depends on: the template for in vitro transcription, the transfer plasmid for viral vector production, and the backbone of non-viral gene delivery. Global demand for pharmaceutical-grade pDNA has grown faster than production capacity, and optimizing E. coli fermentation is the primary lever available to close that gap.

Key takeaways

E. coli is the universal production host for pharmaceutical-grade plasmid DNA because of its well-characterized genetics, high plasmid copy number in established high-copy vectors, and established GMP fermentation infrastructure. The challenge is not whether E. coli can produce pDNA at scale, but how to engineer the fermentation to maximize yield, supercoiled isoform content, and batch-to-batch consistency simultaneously.

Acetate accumulation is the primary metabolic constraint on E. coli pDNA production at high cell density. When glucose uptake exceeds the oxidative capacity of the TCA cycle, overflow metabolism generates acetate, which inhibits cell growth and reduces plasmid stability. Fed-batch fermentation with controlled glucose feeding is the standard strategy for managing acetate formation at commercially relevant cell densities.

Supercoiled plasmid content, the fraction of total pDNA in the pharmacologically active covalently closed circular (ccc) isoform, is a quality specification as well as a production performance metric. The FDA recommends greater than 80% supercoiled content for gene therapy applications. This specification constrains fermentation conditions, harvest timing, and downstream processing simultaneously.

Animal-origin-free (AOF) media eliminates the BSE and TSE compliance risk from conventional pDNA fermentation media containing animal-derived peptones or yeast extracts. Transitioning from complex animal-origin media to chemically defined or semi-defined AOF formulations typically requires re-optimization of cell growth kinetics and carbon source management to maintain pDNA yield.

Downstream purification of pharmaceutical-grade pDNA must remove RNA, chromosomal DNA, host cell protein, and endotoxin to route-of-administration-specific limits while preserving the supercoiled isoform fraction. Alkaline lysis provides selective denaturation of chromosomal DNA, and anion exchange chromatography selectively elutes the supercoiled isoform from open circular and linear contaminants.

Plasmid DNA is the shared upstream dependency that connects mRNA manufacturing, viral vector production, and non-viral gene delivery in a single supply chain bottleneck. For the viral vector manufacturing context in which pDNA serves as the triple transfection raw material, see scaling up viral vector manufacturing for gene therapies. For the full advanced therapy manufacturing overview, see scaling the unscalable: manufacturing cell, gene, and mRNA therapies.

How E. coli becomes a plasmid factory: the production biology

E. coli produces plasmid DNA as a natural consequence of plasmid maintenance: high-copy plasmids based on the ColE1 origin of replication, including the widely used pUC and pBR322-derived backbones, autonomously replicate to copy numbers of 500 to 700 per cell under standard culture conditions. This native replication mechanism makes E. coli a highly productive pDNA host without requiring the expression system engineering needed for protein biopharmaceuticals. The challenge is that plasmid replication is coupled to cell growth, and the conditions that maximize cell density do not always maximize specific pDNA yield per cell or total supercoiled content.

The choice of production strain significantly affects yield and quality. The commonly used E. coli DH5alpha strain is a robust pDNA producer but tends to accumulate acetate at high glucose concentrations, which inhibits growth and reduces plasmid stability in extended fermentations. Strain engineering work published in Microbial Cell Factories demonstrated that a triple-knockout E. coli strain with recA, deoR, and nupG deletions produced 186 milligrams per liter of pDNA at 40 grams per liter biomass with only 2.2 grams per liter acetate, compared to 70 milligrams per liter and 9.5 grams per liter acetate for standard DH5alpha under equivalent glucose conditions. Maintaining antibiotic selection pressure throughout the fermentation, typically using kanamycin resistance rather than ampicillin for GMP applications, prevents plasmid-cured cells from outcompeting plasmid-bearing cells during extended high-density culture.

Batch culture of E. coli in shake flasks or small bioreactors under standard conditions typically yields 10 to 30 milligrams of pDNA per liter of culture. Fed-batch fermentation at controlled specific growth rates and high cell density can achieve yields of 100 to 300 milligrams per liter with appropriate process development. The gap between batch and fed-batch yield is primarily due to the ability to maintain cells in an active growth-and-replication state over an extended period rather than allowing growth to cease as nutrients are depleted.

What fermentation parameters most affect pDNA yield and supercoiled content?

Specific growth rate is the single most influential fermentation parameter affecting both pDNA yield and supercoiled isoform content. Research on sulfate limitation as a strategy for increasing pDNA yield in fed-batch E. coli fermentation confirmed that controlled nutrient limitation can increase the supercoiled pDNA fraction by 33% and volumetric productivity by 13% by extending the stationary phase window during which plasmid replication continues without accompanying cell division. This decoupling of cell growth from plasmid replication is a general principle: conditions that slow or arrest cell growth while maintaining metabolic activity can improve specific pDNA yield per gram of biomass, because the cell's replication machinery continues working on plasmid maintenance after chromosomal replication has slowed.

Temperature is the most directly controllable fermentation parameter affecting supercoiled content. Higher fermentation temperatures increase DNA gyrase activity, which is the primary enzyme responsible for maintaining negative supercoiling in E. coli plasmids. However, higher temperatures also increase the rate of plasmid nicking by thermally activated nucleases and reduce plasmid stability in extended cultures. Most GMP pDNA fermentations operate in the range of 30 to 37 degrees Celsius, with the lower end of this range used when supercoiled content is the primary optimization target.

Dissolved oxygen management affects pDNA yield through its interaction with glucose metabolism. Oxygen limitation at high cell density promotes the shift from fully oxidative glucose metabolism toward mixed acid fermentation, increasing acetate production. Maintaining dissolved oxygen above 30% air saturation during the production phase prevents the metabolic shift toward acetate overflow and preserves the aerobic TCA cycle activity that supports plasmid replication. Cascade control using agitation speed and airflow rate is standard in GMP bioreactors to maintain dissolved oxygen setpoints at high cell densities.

Strategy	Mechanism	Typical yield	Supercoiled fraction	Key consideration
Batch culture, DH5alpha	Standard replication coupled to cell growth; no nutrient control	10-30 mg/L	60-80%; variable with harvest timing	Simple setup; acetate accumulation limits cell density; baseline for process comparison
Fed-batch, exponential glucose feed	Controlled glucose feed maintains target specific growth rate; prevents acetate overflow; extends production phase	100-200 mg/L	75-85%; improved by controlled growth rate	Standard GMP approach; requires bioreactor with feed control; oxygen cascade control needed at high density
Nutrient limitation (sulfate or phosphate)	Controlled depletion of secondary nutrient decouples growth from plasmid replication in stationary phase; extends active production window	100-250 mg/L; 13% productivity improvement confirmed	Up to 33% improvement over non-limited fed-batch confirmed in literature	Requires nutrient modeling; sulfate limitation approach confirmed in 2023 peer-reviewed study
Strain engineering (recA, deoR, nupG knockouts)	Metabolic engineering reduces acetate accumulation and plasmid degradation; improved yield per gram biomass	Up to 186 mg/L reported for VH33 triple mutant vs. 70 mg/L for DH5alpha at equivalent glucose	High supercoiled stability maintained throughout cultivation	Requires custom strain; additional cell banking and characterization for GMP; beneficial for commercial-scale programs

Animal-origin-free media: eliminating the compliance risk in GMP fermentation

Conventional complex E. coli fermentation media contain animal-derived components, most commonly beef peptone, tryptone, and casein hydrolysates. These ingredients support high cell density by providing a ready source of amino acids, peptides, and growth factors that the cells do not need to synthesize de novo. They are also inexpensive and widely characterized for E. coli growth performance. The regulatory problem is that animal-origin ingredients in GMP pharmaceutical production carry a risk of bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE) contamination that requires extensive supplier qualification and documentation under EMA and FDA guidelines.

Animal-origin-free (AOF) media replaces conventional animal-derived ingredients with components derived from plant sources, microbial fermentation, or synthetic chemistry. Soy peptones, wheat hydrolysates, and chemically defined synthetic amino acid mixtures are the most common replacements. Fully chemically defined AOF media, in which every component is a defined pure chemical, provide the highest regulatory simplicity for GMP drug master file submissions but typically require the most process development work to match the yield performance of complex media.

The transition from animal-origin to AOF media typically requires re-optimization of cell growth kinetics, carbon-to-nitrogen ratio, and the feeding profile in fed-batch fermentations. AOF media formulations that support equivalent or near-equivalent E. coli growth rates and pDNA yield performance are achievable, but the optimized conditions differ from those developed with animal-origin media and cannot be assumed to transfer directly without validation data. Programs that establish GMP-grade pDNA production should design for AOF media from the outset rather than planning a retrospective switch, because media changes after GMP fermentation establishment typically require comparability studies and may require regulatory notification.

Why does the plasmid isoform ratio matter and how is supercoiled content controlled?

Plasmid DNA exists in three isoforms that differ in topological structure and biological activity. The supercoiled or covalently closed circular (ccc) isoform is the therapeutically active form: its tightly wound topology confers resistance to nuclease degradation, more efficient cellular uptake in non-viral delivery, and superior IVT reaction performance in mRNA manufacturing. The open circular (oc) isoform results from a single-strand nick in the ccc form, relaxing the supercoiling. The linear isoform results from a double-strand break. Both open circular and linear forms are considered impurities in pharmaceutical-grade pDNA and are less effective in all downstream applications.

The FDA recommends greater than 80% supercoiled content for plasmid DNA used in gene therapy applications, as confirmed in research on cell engineering strategies to enhance supercoiled pDNA production. This specification places a quality constraint on both the fermentation process and the downstream purification train, because supercoiled content can be lost at every step where the plasmid encounters mechanical shear, elevated temperature, or endonuclease activity. The fermentation harvest time is a critical control point: extending fermentation beyond the optimal harvest window allows nucleases and topoisomerases from lysing cells to begin degrading and relaxing the supercoiled fraction.

For mRNA manufacturing, supercoiled percentage carries additional significance as an in-process control because the IVT reaction performance, and therefore the mRNA yield and quality, depends on the template topology. Research confirming supercoiled DNA percentage as a key IPC of the linear DNA template for mRNA drug substance manufacturing demonstrated that the fraction of supercoiled template before linearization directly influences mRNA product quality, establishing supercoiled percentage in the pDNA starting material as a critical upstream control rather than a finishing specification.

Downstream strategies for supercoiled enrichment include anion exchange chromatography under optimized salt gradient conditions that exploit the slightly different charge display of supercoiled versus relaxed isoforms, and selective precipitation or size-based fractionation. None of these approaches can substantially increase supercoiled content beyond what the upstream process delivers; they can selectively remove the open circular and linear contaminants that accumulate in the upstream process, but the total amount of supercoiled isoform available for recovery is fixed by fermentation and lysis performance.

Downstream processing: from alkaline lysis to pharmaceutical-grade pDNA

Plasmid DNA purification from E. coli is based on alkaline lysis, a selective denaturation method that exploits the topological difference between the supercoiled plasmid and the linear chromosomal DNA. At pH values between 12 and 12.5, achieved by adding sodium hydroxide and SDS, the chromosomal DNA denatures, and the cell proteins precipitate, but the supercoiled plasmid remains intact because its interlocked circular topology prevents the complete strand separation required for irreversible denaturation. Neutralization by potassium acetate precipitates the denatured chromosomal DNA and cell debris as a white curd, which is removed by centrifugation or depth filtration to yield a clarified lysate containing the pDNA, RNA, host cell protein, and endotoxin.

The clarified lysate requires multi-step chromatographic purification to reach pharmaceutical grade. A primary capture step using anion exchange chromatography binds all negatively charged nucleic acids and then selectively elutes the supercoiled pDNA fraction under salt gradient conditions. RNA, which is present in large excess over pDNA in E. coli lysate, can be removed by a ribonuclease treatment step followed by a second anion exchange separation, or by using size-based fractionation methods that discriminate between the large plasmid and the smaller RNA fragments. Host cell protein is removed by the combination of alkaline lysis precipitation and the chromatographic steps. Endotoxin, which is a major impurity concern for injectable drug products, is removed by specialized anion exchange or hydrophobic charge induction chromatography under conditions that bind the lipopolysaccharide while allowing the pDNA to pass through.

Final polishing and concentration by tangential flow filtration delivers a concentrated pDNA drug substance in formulation buffer, typically 10 mM Tris-HCl or Tris-EDTA at physiological pH, ready for in-process testing and release. Sterile filtration through a 0.22-micrometer membrane provides bioburden reduction for injectable applications. The complete downstream train from clarified lysate to final drug substance typically takes two to three days and requires three to five chromatographic steps, with overall recovery of the supercoiled fraction from clarified lysate to final drug substance in the range of 50 to 70 percent when all steps are optimized.

What quality attributes define a GMP-grade pDNA specification?

GMP-grade plasmid DNA for pharmaceutical use must meet a set of release specifications that address the identity, purity, potency, and safety of the product. The specific limits depend on the intended use: pDNA for injectable gene therapy carries stricter endotoxin limits than pDNA used as an in vitro transcription template in a manufacturing process where the pDNA itself does not enter the patient. The core quality attributes that apply across applications are established by FDA and EMA guidance on gene therapy manufacturing and biological product quality.

Quality attribute	Typical specification	Analytical method	Significance
Supercoiled (ccc) content	Greater than 80%; FDA recommendation for gene therapy applications	Agarose gel electrophoresis; HPLC	Primary indicator of product quality and biological activity; direct predictor of IVT efficiency in mRNA manufacturing
Residual RNA	Less than 1% (w/w) of total nucleic acid	Agarose gel; HPLC; A260/A280 ratio	RNA contamination interferes with transfection efficiency and IVT reaction performance; indicates incomplete downstream purification
Residual host cell protein	Less than 1 nanogram per microgram of pDNA; application-specific	ELISA (E. coli HCP assay)	Host cell protein at high levels can trigger immunogenic responses in gene therapy applications; indicator of purification process effectiveness
Endotoxin	Less than 1 EU/microgram for injectable products; stricter for intrathecal or intraventricular administration	LAL (limulus amebocyte lysate) test; recombinant factor C assay	E. coli is a gram-negative bacterium; its outer membrane releases endotoxin during lysis. Endotoxin is a primary safety concern for parenteral applications
Residual chromosomal DNA	Typically undetectable or less than 1% of total nucleic acid	Hybridization assay; qPCR for E. coli genomic sequences	Chromosomal DNA contamination represents process failure at alkaline lysis or clarification; also indicates process risk for integration of E. coli sequences
Antibiotic resistance marker	Kanamycin preferred for GMP products; ampicillin use requires justification due to beta-lactam hypersensitivity risk	Sequence confirmation; functional resistance assay	Ampicillin resistance gene encodes beta-lactamase which can degrade ampicillin and sensitize patients with penicillin allergy; kanamycin resistance preferred in GMP

This article was produced under Drug Discovery News' AI Editorial Guidelines.

Frequently Asked Questions (FAQs)

Why is E. coli the preferred production organism for pharmaceutical-grade pDNA?
E. coli naturally maintains high-copy ColE1-origin plasmids at 500 to 700 copies per cell without requiring the expression system engineering needed for protein production. Its fermentation at GMP scale is well-established, its genetics are fully characterized, and its growth on defined carbon sources supports the transition to animal-origin-free media. No alternative host organism provides comparable plasmid copy number, fermentation scalability, and regulatory precedent for pharmaceutical pDNA manufacturing.
What causes acetate accumulation in E. coli pDNA fermentation and why is it a problem?
Acetate accumulates when glucose uptake exceeds the capacity of the TCA cycle to process the resulting pyruvate oxidatively, diverting carbon through overflow fermentation to acetate and other organic acids. Acetate inhibits E. coli growth at concentrations above 3 to 5 grams per liter, reducing cell density and plasmid yield. Fed-batch operation with controlled glucose feeding prevents the glucose excess that drives overflow metabolism, keeping acetate below inhibitory concentrations throughout the fermentation.
What is animal-origin-free media and why does it matter for GMP pDNA production?
AOF media replaces animal-derived ingredients such as beef peptone and casein hydrolysates with plant-derived or synthetic components, eliminating the BSE and TSE risk that requires extensive supplier qualification under regulatory guidelines. For GMP drug master file submissions to FDA and EMA, AOF media simplifies the raw material risk assessment and reduces the documentation burden for each production lot. Programs should establish AOF media from the start of GMP development rather than planning a later switch, which requires comparability studies.
Why does supercoiled content matter so much for pDNA quality?
The supercoiled isoform is the biologically active form of plasmid DNA: it is more resistant to nuclease degradation, more efficiently taken up by cells in non-viral delivery, and more productive as an in vitro transcription template for mRNA manufacturing. The FDA recommends greater than 80% supercoiled content for gene therapy applications. Downstream processing can selectively remove open circular and linear contaminants, but cannot increase the total pool of supercoiled pDNA beyond what the upstream process produces.
How are endotoxins removed from E. coli-derived pDNA?
Endotoxins, the lipopolysaccharides released from E. coli's outer membrane during cell lysis, are negatively charged amphiphilic molecules that bind anion exchange resins alongside pDNA. Selective elution under conditions that favor pDNA desorption before endotoxin, or anion exchange chromatography operated in a mode where endotoxin is retained while pDNA passes through, are the primary removal strategies. Hydrophobic charge induction chromatography can also separate endotoxin from pDNA based on the hydrophobic character of the lipid A component. Multi-step purification trains typically achieve endotoxin removal to below 1 EU per microgram for injectable applications.

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Trevor J Henderson
Trevor Henderson is the Creative Services Director for the Laboratory Products Group at LabX Media Group. With over two decades of experience, he specializes in scientific and technical writing, editing, and content creation. His academic background includes training in human biology, physical anthropology, and community health. Since 2013, he has been developing content to engage and inform scientists and laboratorians.
View Full Profile